Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02373046 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets
A Phase 1 study, sponsored by Lexicon Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02373046 is a Phase 1 study that has completed, run by Lexicon Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT02373046, a Phase 1 study, has completed, sponsored by Lexicon Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a randomized, single-center, open-label, 2-sequence, 2-period, single-dose, crossover study to assess the bioequivalence and the total 24-hour urinary glucose excretion (UGE) of 400 mg LX4211 administered as a single 400-mg tablet compared to 2 × 200-mg tablets in healthy subjects under fasted conditions.
Interventions
- DRUG LX4211
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02373046
The ClinicalTrials.gov registry entry for NCT02373046 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lexicon Pharmaceuticals, which has 56 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LX4211 is the first listed.
NCT02373046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02373046 about?
NCT02373046 is a clinical study titled "Bioequivalence Study Between 400 mg LX4211 Tablets and 2 X 200 mg LX4211 Tablets". This is a randomized, single-center, open-label, 2-sequence, 2-period, single-dose, crossover study to assess the bioequivalence and the total 24-hour urinary glucose excretion (UGE) of 400 mg LX4211 administered as a single 400-mg tablet compared to 2 × 200-mg tablets in healthy subjects under fast...
What is the current status of trial NCT02373046?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2015-02.
What interventions are being tested in trial NCT02373046?
The interventions under investigation include: LX4211 (DRUG).
Who is sponsoring clinical trial NCT02373046?
This trial is sponsored by Lexicon Pharmaceuticals, which has 56 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.